2 new antibody tests get FDA clearance

Apr 16, 2020

The U.S. Food and Drug Administration (FDA) has issued emergency use authorization (EUA) for two new tests that detect the presence of antibodies to the virus that causes COVID-19.

The authorizations were issued to Ortho Clinical Diagnostics for its Vitros Immunodiagnostic Products Anti-SARS-CoV-2 total reagent pack and Chembio Diagnostic Systems for its DPP COVID-19 IgM/IgG system.

Both serology tests can detect immunoglobulin M/immunoglobulin G (IgM/IgG) antibodies from serum or plasma samples of patients suspected of having COVID-19. The DPP COVID-19 IgM/IgG system can also detect antibodies in venous whole blood or whole blood specimens.

2 new antibody tests get FDA clearance

Prenosis gets FDA authorization for AI-based sepsis diagnostic tool

Visit our Molecular Diagnostics Community

BioMérieux gets FDA 510(k) clearance, CLIA waiver approval for panel

Boston Scientific gets FDA approval for drug-coated balloon catheter

Prenosis gets FDA authorization for AI-based sepsis diagnostic tool

Basilea gets FDA approval for antibiotic

BioMérieux gets FDA 510(k) clearance, CLIA waiver approval for panel

Boston Scientific gets FDA approval for drug-coated balloon catheter

FDA grants accelerated approval to Iovance’s melanoma cell therapy

T2 Biosystems gets FDA nod to expand bacteria panel

Why many high-risk IVDs are being reclassified

Imvaria gets FDA marketing authorization for Fibresolve

FDA approves test for opioid use disorder risk assessment

FDA approves Abbott laboratory automation system

FDA clears BD’s new fingerstick blood collection device

KSQ Therapeutics receives FDA clearance for trial of CRISPR-Cas9 engineered tumor therapy